• Price (EUR)30.03
  • Today's Change-0.18 / -0.60%
  • Shares traded0.00
  • 1 Year change-31.90%
  • Beta--
Data delayed at least 15 minutes, as of Jan 26 2023.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Arrowhead Pharmaceuticals Inc had net income fall 25.00% from a loss of 140.85m to a larger loss of 176.06m despite a 75.89% increase in revenues from 138.29m to 243.23m.
Gross margin--
Net profit margin-72.56%
Operating margin-73.39%
Return on assets-25.18%
Return on equity-43.62%
Return on investment-32.18%
More ▼

Cash flow in USDView more

In 2022, cash reserves at Arrowhead Pharmaceuticals Inc fell by 76.43m. Cash Flow from Financing totalled 65.19m or 26.80% of revenues. In addition the company used 136.13m for operations while cash used for investing totalled 5.42m.
Cash flow per share-1.57
Price/Cash flow per share--
Book value per share3.76
Tangible book value per share3.65
More ▼

Balance sheet in USDView more

Arrowhead Pharmaceuticals Inc uses little or no debt in its capital structure.
Current ratio2.92
Quick ratio--
Total debt/total equity0.00
Total debt/total capital0.00
More ▼
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.